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Drug resistance in malaria parasites is one of the major stumbling blocks hindering the goal of malaria elimination. One 
of the major strategies to counter drug resistance is the development of new potent antimalarial drugs. In the present study, a 
series of novel sulfonamide based coumarin-[1,2,3]-triazole conjugates have been synthesized via Huisgen reaction between 
azidosulfonamides and 4-hydroxy- or 7-hydroxymethylcoumarinoalkynes. All the compounds have been characterized 
spectroscopically and screened for their in vitro antimalarial activity against P. falciparum 3D7 strain. Out of the twenty five 
synthesized compounds, four compounds displayed significant activity (IC50 <10 µM) with the most active compound 
having an IC50 of 3.64 µM. 
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Malaria is a mosquito-borne parasitological disease 
prominent in tropical and subtropical regions of the 
world. It is caused by the parasites of the genus 
Plasmodium (P.) and is transmitted by female 
Anopheles mosquitoes. There are five species of 
malaria parasites that infect humans, namely P. 
falciparum, P. vivax, P. ovale, P. malariae, and P. 
knowlesi. Among these, P. falciparum is responsible 
for causing the most lethal form of malaria and the 
majority of malaria-related mortality and morbidity1.  
P. falciparum is gradually becoming resistant to
commonly used antimalarial drugs. P. falciparum
strains occurring in most malaria endemic countries
have become completely resistant to the majority of
antimalarial drugs including chloroquine, mefloquine,
and sulfadoxine/pyrimethamine1,2. Moreover, P.
falciparum strains in the South-East Asia region have
already started to show signs of reduced
efficacy/partial resistance to the most potent malaria
drug of the present era, artemisinin2. In the absence of
a safe and effective transmission-blocking drug,
preventing the widespread transmission of 
artemisinin-resistant parasites to other areas is
extremely challenging and crucial3-7. Potential
dissemination of artemisinin-resistant parasites
outside of South-East Asia, especially to sub-Saharan
Africa, where the malaria burden is on the higher side, 
can have disastrous consequences. Therefore, to 
tackle the threat of drug resistance and to increase the 
ammunition against the malaria parasite, researchers 
worldwide are focused on discovering novel 
antimalarial drugs with a unique mechanism of action. 
To this end, our group is routinely involved in 
synthesizing hybrid antimalarial compounds with 
multiple pharmacologically significant moieties, 
including quinoline, triazole, sulfonamide and 
berberine8-10. In continuation with our previous efforts 
of developing potent sulfonamide based hybrid 
antimalarials, we have used the sulfonamide moiety 
as a base for synthesizing novel antimalarials. 
Sulfonamide is the same moiety present in one of the 
prominent antimalarial drugs of today, sulfadoxine. 
Developing drugs based on a sulfonamide moiety is 
expected to result in compounds with similar cross 
resistance patterns as sulfadoxine. They would thus 
illicit drug resistance earlier in areas already 
harboring sulfadoxine resistance. Therefore, to 
broaden the structural diversity of the compounds and 
to delay the onset of drug resistance, sulfonamide 
moiety is appended to another class of heterocycles, 
the coumarins (2H-chromen-2-ones), by [1,2,3]-
triazole linkers to yield prospective antimalarial drug 




candidates. Coumarins are an important class of 
oxygen heterocycles composed of fused benzene and 
α-pyrone rings. They are released as secondary 
metabolites during metabolism in bacteria, fungi  
and plants, and possess a myriad of biological 
properties including antioxidant11, antimalarial12, 
antitumor13, antifungal14, cytotoxic15, anti-inflammatory16 
antiprotozoal17, anti-HIV18, antidiabetic19, and antiviral 
properties20. Moreover, a naturally occurring  
4-phenylcoumarin derivative inophyllum A, which has 
two fused pyran rings, is reported to be as antitumor 
and anti-HIV agents21. Similarly, other naturally 
occurring neoflavones (Figure 1) such as coutareagenin, 
(±)-inophyllum E, apetalolide, interruptin A, and 
ponnalide also have diverse pharmacological 
properties22. For instance, coutareagenin (5-hydroxy-7-
methoxy-4-(3,4-dihydroxyphenyl)-2H-benzo-1-pyran-
2-one) isolated from the bark of Hintonia latiflora, 
helps in controlling blood sugar levels in diabetic 
patients22. Similarly, [1,2,3]-triazole is another 
pharmacologically relevant moiety present in various 
antimalarial9,10, antifungal23, antibacterial24 and 
antitubercular compounds25. 
Therefore, in the present study, novel chemical 
entities with three ‘biologically privileged’ 
pharmacophores were obtained by the reaction of 
various coumarinoalkynes with sulfonamide-based 
azides under click reaction conditions. These 
compounds were then characterized based on 
spectroscopic data and evaluated for their antimalarial 
potential in culture. 
 
Results and Discussion 
 
Synthesis 
For the synthesis of desired sulfonamide-appended 
coumarin-[1,2,3]-triazoles, azides (1a-e) were 
synthesized from the corresponding sulfonamide 
amines via diazotization in the presence of 
concentrated HCl and sodium nitrite followed by the 
reaction with NaN3 according to the literature 
procedure26. On the other hand, the coumarinoalkynes 
(3 and 5a-d) were prepared in good to excellent  
yields by the reaction of propargyl bromide and 
commercially available 2H-chromen-2-ones in 
acetone containing K2CO3 as a base at 60°C for 8 
hours. After chromatographic purification, the 
respective terminal alkynes were characterized 
spectroscopically and their spectral data are found in 
agreement with the reported data27. Finally, desired 
sulfonamide-appended coumarin-[1,2,3]-triazoles (6a-
e, 7a-d, 8a-d, 9a-d, 10a-d, and 11a-c) were prepared 
via a Cu(I)-catalyzed Huisgen [3+2] cycloaddition 
reaction of sulfonamide based azides (1a-e) and 
terminal alkynes of 4-hydroxy and 7-hydroxy 
coumarins (3 and 5a-d) in the presence of sodium 
ascorbate and CuSO4.5H2O in an equimolar  



































Figure 1 — Structures of some biologically active naturally occurring coumarin derivatives 






Antimalarial activity evaluation against P. falciparum 3D7 
Antimalarial activity of the synthesized sulfonamide-
appended coumarin-[1,2,3]-triazoles (6a-e, 7a-d, 8a-d, 
9a-d, 10a-d, and 11a-c) was evaluated against 3D7 
strain of P. falciparum by radioactive [3H] hypoxanthine 
incorporation inhibition assay as previously described9. 
All the tested compounds demonstrated IC50 values in 
the micromolar range (3.64 µM to 100 µM). The most 
promising compound in terms of antimalarial activity 
was found to be 7c, a 1,2,3-triazole bearing primary 
sulfonamide and 7-hydroxymethyl-4-methyl-2H-
chromen-2-one moieties (IC50 = 3.64 µM). Another 
primary sulfonamide-appended coumarin-[1,2,3]-
triazole hybrid, 7b, with an IC50 value of 3.68 µM was 
not far behind than the lead compound, 7c. Among the 
other hybrid molecules, the [1,2,3]-triazole, 10c tethered 
with 7-hydroxy-4-methylcoumarin and a tertiary 
sulfonamide bearing morpholine scaffold also showed 
remarkable potency with IC50 of 5.18 µM. This was 
followed by compound 7d with an IC50 value 8.96 µM. 
The results of in vitro antimalarial activity are 
summarized in Table I. 
 
Materials and Methods 
The chemicals and solvents were purchased from 
Sigma-Aldrich, Merck, Spectrochem and SD Fine 
Chemicals and used as received without further 
purification. Thin layer chromatography was performed 
on silica gel 60 F254 (pre-coated aluminium sheets) 
from Merck. 1H NMR and 13C NMR spectra were 
recorded either in CDCl3 or in DMSO-d6, using TMS 
as an internal standard on Jeol ECX 400 MHz NMR 
spectrometer. Chemical shifts are reported in parts  
per million (ppm), and coupling constants (J) are 
expressed in Hertz (Hz). Infrared spectra were 
recorded on Perkin-Elmer IR spectrometer and 
absorption maxima (νmax) were measured in cm-1. 
High resolution mass spectra were recorded on 
Agilent G6530 AA LC-HRMS Q-TOF mass 
spectrometer. Melting points were recorded in open 
capillary tubes and are uncorrected. 
 
Experimental Section 
General procedure for the synthesis of 
sulfonamide-coumarin-[1,2,3]-triazoles 6a-e, 7a-d, 
8a-d, 9a-d, 10a-d and 11a-c 
To a well stirred solution of azides (1a-e; 1 mmol) 
and alkynes (3 and 5a-d; 1.1 mmol) in t-BuOH  
(4 mL), a solution of sodium ascorbate (0.4 mmol) in 
water (2 mL) was added. After 10 minutes, a solution 
of CuSO4.5H2O (0.6 mmol) in water (2 mL) was 
added, and the reaction mixture was stirred at 50°C 
for 5 hours under an inert atmosphere. On completion  
 
 
Scheme I — Synthesis of sulfonamide-attached coumarin-[1,2,3]-triazole hybrids 
 





Table I — Isolated yields and in vitro antimalarial activity of sulfonamide-appended coumarin-[1,2,3]-triazoles  
(6a-e, 7a-d, 8a-d, 9a-d, 10a-d and 11a-c) 
Compd R R1 R2 R3 Yield* (%) Antimalarial activity  
(after 42 h) 
IC50 (µg/mL) IC50 (µM) 
6a NH2 − − − 92 40 100.50 
6b 
 
− − − 70 >40 >79.36 
6c 
 
− − − 88 >40 >85.83 
6d 
 
− − − 
85 16 34.18 
6e 
 
− − − 82 40 73.52 
7a NH2 H H H 90 20 50.25 
7b NH2 CH3 Ph H 82 1.8 3.68 
7c NH2 H CH3 H 94 1.5 3.64 
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Table I — Isolated yields and in vitro antimalarial activity of sulfonamide-appended coumarin-[1,2,3]-triazoles  
(6a-e, 7a-d, 8a-d, 9a-d, 10a-d and 11a-c) (Contd.) 
Compd R R1 R2 R3 Yield* (%) Antimalarial activity  
(after 42 h) 


















H H H 85 >40 85.65 
9b 
 
CH3 Ph H 80 40 71.81 
9c 
 
H CH3 H 88 28 58.33 
9d 
 
H CH3 Cl 83 40 77.82 
10a 
 
H H H 88 >40 >85.47 
10b 
 
CH3 Ph H 80 40 71.68 
10c 
 
H CH3 H 82 2.5 5.18 
10d 
 
H CH3 Cl 85 26 50.38 
11a 
 
H H H 78 >40 >73.52 
11b 
 
H CH3 H 79 >40 >71.68 
11c 
 
H CH3 Cl 75 35 59.12 
Chloroquine − − − − − 0.034 0.066 
*Isolated yields 
 





of the reaction, the desired product was extracted with 
ethyl acetate (20 mL × 5 times), and the organic layer 
was washed with brine solution (30 mL × 4 times) 
followed by water (20 mL × 5 times). The organic 
layer was dried over anhydrous Na2SO4 and 
evaporated to dryness. Thus, the solid obtained was 
triturated with chloroform and filtered to afford the 
title compounds in good to excellent yields. 
4-(4-(((2-Oxo-2H-chromen-4-yl)oxy)methyl)-1H-
1,2,3-triazol-1-yl)benzenesulfonamide 6a: Crimson 
solid. Yield 92%. m.p.245-247°C; IR (KBr) νmax: 
3301, 3080, 2926, 2370, 2345, 1701, 1618, 1379, 
1342, 1276, 1248, 1192, 1159, 1109, 1046, 941, 842, 
774, 755, 619, 550 cm-1; 1H NMR (400 MHz, DMSO-
d6): δ 9.18 (s, 1H, triazole H), 8.17 (d, 2H, J = 9.16 
Hz, ArH), 8.04 (d, 2H, J = 9.16 Hz, ArH), 7.84 (d, 
1H, J = 8.39 Hz, ArH), 7.67 (t, 1H, J = 7.63 Hz, 
ArH), 7.56 (s, 2H, NH2), 7.42 (d, 1H, J = 8.39 Hz, 
ArH), 7.35 (t, 1H, J = 7.63 Hz, ArH), 6.21 (s, 1H, 
CH), 5.54 (s, 2H, OCH2); 13C NMR (100 MHz, 
DMSO-d6): δ 164.35, 161.58, 152.80, 144.06, 142.67, 
138.49, 132.92, 127.55, 124.28, 123.64, 123.08, 
120.60, 116.52, 115.05, 91.54, 62.76; HRMS (ESI): 




yl)benzenesulfonamide 6b: Light brown solid. Yield 
70%. m.p.277-279°C; IR (KBr) νmax: 3432, 3166, 
2925, 2370, 1773, 1745, 1611, 1599, 1560, 1508, 
1437, 1405, 1358, 1295, 1236, 1165, 1145, 1095, 
1054, 875, 835, 787, 747, 608, 577, 459 cm-1; 1H 
NMR (400 MHz, DMSO-d6): δ 9.01 (s, 1H, triazole 
H), 8.09 (brs, 2H, ArH), 7.98 (brs, 2H, ArH), 7.56 (d, 
1H, J = 7.79 Hz, ArH), 7.53 (d, 1H, J = 7.33 Hz, 
ArH), 7.31 (d, 1H, J = 7.79 Hz, ArH), 7.24 (s, 1H, 
ArH), 6.95 (d, 1H, J = 7.33 Hz, ArH), 6.82 (s, 1H, 
CH), 5.34 (s, 2H, OCH2), 1.82 (s, 6H, 2CH3); HRMS 
(ESI): Calcd for C24H21N6SO5: m/z = 505.1300 
[M+H]+, found: 505.1262. 
4-((1-(4-(Piperidin-1-ylsulfonyl)phenyl)-1H-1,2, 
3-triazol-4-yl)methoxy)-2H-chromen-2-one 6c: Pale 
yellow solid. Yield 88%. m.p.252-254°C; IR (KBr) 
νmax: 3088, 2925, 2832, 2371, 2345, 1717, 1621, 
1597, 1508, 1451, 1420, 1405, 1375, 1360, 1344, 
1310, 1274, 1244, 1194, 1169, 1150, 1140, 1105, 
1060, 1025, 980, 935, 885, 843, 754, 707, 602, 583 
cm-1; 1H NMR (400 MHz, DMSO-d6): δ 9.24  
(s, 1H, triazole H), 8.23 (d, 2H, J = 8.56 Hz, ArH), 
7.96 (d, 2H, J = 8.56 Hz, ArH), 7.84 (d, 1H, J = 7.34 
Hz, ArH), 7.67 (t, 1H, J = 7.34 Hz, ArH), 7.42 (d, 1H, 
J = 7.34 Hz, ArH), 7.35 (t, 1H, J = 7.34 Hz, ArH), 
6.20 (s, 1H, CH), 5.55 (s, 2H, OCH2), 2.95 (t, 4H, J = 
4.89 Hz, piperidine H), 1.58-1.51 (m, 4H, piperidine 
H), 1.37 (brs, 2H, piperidine H) ppm; HRMS (ESI): 
Calcd for C23H23N4SO5: m/z = 467.1384 [M+H]+, 
found: 467.1409. 
4-((1-(4-(Morpholinosulfonyl)phenyl)-1H-1,2,3-
triazol-4-yl)methoxy)-2H-chromen-2-one 6d: Grey 
solid. Yield 85%. m.p.210-212°C; IR (KBr) νmax: 
3116, 2841, 1707, 1614, 1564, 1504, 1442, 1411, 
1354, 1323, 1298, 1244, 1163, 1143, 1101, 1045, 987, 
939, 883, 840, 754, 717, 644, 594, 538, 499 cm-1; 1H 
NMR (400 MHz, DMSO-d6): δ 9.17 (s, 1H, triazole 
H), 8.23 (brs, 2H, ArH), 7.96 (brs, 2H, ArH), 7.57 
(brs, 1H, ArH), 7.32 (brs, 1H, ArH), 7.26 (brs, 1H, 
ArH), 6.95 (brs, 1H, ArH), 6.85 (s, 1H, CH), 5.38 (s, 
2H, OCH2), 3.64 (brs, 4H, morpholine H), 2.93 (brs, 
4H, morpholine H); HRMS (ESI): Calcd for 




chromen-2-one 6e: Grey solid. Yield 82%; mp: 240-
242°C; IR (KBr) νmax: 2848, 1708, 1618, 1591, 1564, 
1481, 1436, 1348, 1309, 1273, 1242, 1161, 1110, 
1047, 1016, 979, 947, 842, 761, 599, 570 cm-1; 1H 
NMR (400 MHz, DMSO-d6): δ 9.14 (s, 1H, triazole 
H), 8.20 (brs, 2H, ArH), 8.06 (brs, 1H, pyridyl H), 
7.97 (brs, 3H, ArH, pyridyl H), 7.66 (brs, 1H, ArH), 
7.50 (brs, 1H, pyridyl H), 7.19 (brs, 1H, ArH), 7.05 
(brs, 1H, ArH), 6.80 (brs, 1H, ArH), 6.63 (brs, 1H, 
pyridyl H), 6.31 (s, 1H, CH), 5.37 (s, 2H, OCH2), 3.60 
(brs, 4H, piperazine H), 3.03 (brs, 4H, piperazine H); 
HRMS (ESI): Calcd for C27H25N6SO5: m/z = 
545.1607 [M+H]+, found: 545.1611. 
4-(4-(((2-Oxo-2H-chromen-7-yl)oxy)methyl)-1H-
1,2,3-triazol-1-yl)benzenesulfonamide 7a: Light 
brown solid. Yield 90%. m.p.228-230°C; IR (KBr) 
νmax: 3268, 2925, 2369, 2345, 1707, 1609, 1402, 
1327, 1280, 1234, 1163, 1131, 1046, 835, 617, 549 
cm-1; 1H NMR (400 MHz, DMSO-d6): δ 9.10 (s, 1H, 
triazole H), 8.14 (d, 2H, J = 9.16 Hz, ArH), 8.02 (d, 
2H, J = 9.16 Hz, ArH), 7.66 (d, 2H, J = 9.16 Hz, 
ArH), 7.54 (s, 2H, NH2), 7.20 (s, 1H, ArH), 7.06 (d, 
1H, J = 9.16 Hz, CH), 6.31 (d, 1H, J = 9.16 Hz, CH), 
5.38 (s, 2H, OCH2); 13C NMR (100 MHz, DMSO-d6): 
δ 161.00, 160.29, 156.67, 155.32, 144.35, 143.97, 
143.52, 129.60, 127.51, 123.47, 120.51, 112.95, 
112.85, 101.65, 92.73, 61.54; HRMS (ESI): Calcd for 








7b: Off white solid. Yield 82%. m.p.240-242°C; IR 
(KBr) νmax: 3300, 3216, 3082, 2921, 2369, 1707, 
1606, 1369, 1348, 1266, 1179, 1164, 1119, 1072, 
1052, 894, 847, 754, 698, 612, 551 cm-1; 1H NMR 
(400 MHz, DMSO-d6): δ 9.09 (s, 1H, triazole H), 8.14 
(d, 2H, J = 8.39 Hz, ArH), 8.02 (d, 2H, J = 8.39 Hz, 
ArH), 7.57 (d, 2H, J = 7.63 Hz, ArH), 7.55 (s, 2H, 
NH2), 7.53 (s, 1H, ArH), 7.32 (d, 2H, J = 7.63 Hz, 
ArH), 7.26 (d, 1H, J = 2.29 Hz, ArH), 6.96 (dd, 1H,  
1J = 9.16 Hz, 2J = 2.29 Hz, ArH), 6.85 (d, 1H, J = 
9.16 Hz, ArH), 5.37 (s, 2H, OCH2), 1.83 (s, 3H, CH3); 
13C NMR (100 MHz, DMSO-d6): δ 161.60, 160.06, 
153.46, 150.22, 143.99, 143.63, 138.54, 134.68, 
128.97, 128.77, 128.29, 127.78, 127.59, 123.44, 
120.54, 118.83, 114.07, 112.80, 101.65, 61.55, 14.37; 
HRMS (ESI): Calcd for C25H21N4SO5: m/z = 489.1220 
[M+H]+, found: 489.1230. 
4-(4-(((4-Methyl-2-oxo-2H-chromen-7-yl)oxy)- 
methyl)-1H-1,2,3-triazol-1-yl)benzenesulfonamide 
7c: Dark brown solid. Yield 88%. m.p.230-232°C; IR 
(KBr) νmax: 3248, 3189, 3080, 2921, 2367, 1702, 
1617, 1596, 1507, 1394, 1334, 1280, 1162, 1097, 
1054, 991, 912, 853, 834, 745, 611, 553, 447 cm-1; 1H 
NMR (400 MHz, DMSO-d6): δ 9.10 (s, 1H, triazole 
H), 8.14 (d, 2H, J = 8.56 Hz, ArH), 8.03 (d, 2H,  
J = 8.56 Hz, ArH), 7.71 (d, 1H, J = 8.56 Hz, ArH), 
7.53 (s, 2H, NH2), 7.19 (d, 1H, J = 2.45 Hz, ArH), 
7.08 (dd, 1H, 1J = 8.56 Hz, 2J = 2.45 Hz, ArH), 6.23 
(s, 1H, CH), 5.39 (s, 2H, OCH2), 2.40 (s, 3H, CH3); 
13C NMR (100 MHz, DMSO-d6): δ 160.90, 160.11, 
154.67, 153.40, 143.97, 143.57, 138.49, 127.52, 
126.58, 123.40, 120.47, 113.52, 112.60, 111.40, 
101.67, 61.53, 18.15; HRMS (ESI): Calcd for 




7d: Off white solid. Yield 88%. m.p.230-232°C; IR 
(KBr) νmax: 3421, 2922, 2852, 1701, 1595, 1499, 
1412, 1386, 1369, 1342, 1279, 1241, 1207, 1163, 
1085, 1066, 1040, 873, 824, 764, 740, 611, 549 cm-1; 
1H NMR (400 MHz, DMSO-d6): δ 9.11 (s, 1H, 
triazole H), 8.15 (brs, 2H, ArH), 8.03 (brs, 4H, ArH, 
NH2), 7.85 (s, 1H, ArH), 7.51 (s, 1H, ArH), 6.30 (s, 
1H, CH), 5.48 (s, 2H, OCH2), 2.39 (s, 3H, CH3); 
HRMS (ESI): Calcd for C19H16N4SClO5: m/z = 
447.0530 [M+H]+, found: 447.0978. 
N-(4,6-Dimethylpyrimidin-2-yl)-4-(4-(((2-oxo-
2H-chromen-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-
yl)benzenesulfonamide 8a: Light brown solid. Yield 
70%. m.p.224-226°C; IR (KBr) νmax: 3448, 3165, 2924, 
2345, 1745, 1610, 1599, 1560, 1507, 1437, 1404, 1357, 
1294, 1235, 1164, 1145, 1095, 1053, 875, 834, 786, 747, 
607, 576, 459 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 
9.08 (s, 1H, triazole H), 8.17 (d, 2H, J = 8.39 Hz, ArH), 
8.10 (d, 2H, J = 8.39 Hz, ArH), 8.00 (d, 1H, J = 9.16 Hz, 
CH), 7.65 (d, 1H, J = 9.16 Hz, CH), 7.19 (d, 1H, J = 
2.29 Hz, ArH), 7.05 (dd, 1H, 1J = 8.39 Hz, 2J = 2.29 Hz, 
ArH), 6.74 (s, 1H, ArH), 6.30 (d, 1H, J = 8.39 Hz, ArH), 
5.37 (s, 2H, OCH2), 2.26 (s, 6H, 2CH3); 13C NMR (100 
MHz, DMSO-d6): δ 160.99, 160.27, 155.85, 155.32, 
144.31, 143.52, 129.84, 129.60, 123.43, 119.80, 112.93, 
112.82, 112.74, 101.62, 79.30, 78.98, 78.64, 61.53; 
HRMS (ESI): Calcd for C24H21N6SO5: m/z 505.1280 
[M+H]+. Found: 505.1261. 
N-(4,6-Dimethylpyrimidin-2-yl)-4-(4-(((3-methyl- 
2-oxo-4-phenyl-2H-chromen-7-yl)oxy)-methyl)-1H-
1,2,3-triazol-1-yl)benzenesulfonamide 8b: Off white 
solid. Yield 68%. m.p.258-260°C; IR (KBr) νmax: 3448, 
3142, 2924, 2369, 1713, 1598, 1507, 1437, 1400, 1382, 
1293, 1264, 1241, 1165, 1146, 1085, 1045, 984, 871, 
842, 790, 756, 704, 611, 577 cm-1; 1H NMR (400 MHz, 
DMSO-d6): δ 9.06 (s, 1H, triazole H), 8.23 (brs, 2H, 
ArH), 8.04 (brs, 2H, ArH), 7.57 (d, 2H, J = 7.33 Hz, 
ArH), 7.53 (d, 1H, J = 7.33 Hz, ArH), 7.32 (d, 2H, J = 
7.33 Hz, ArH), 7.25 (s, 1H, ArH), 6.95 (d, 1H, J = 7.33 
Hz, ArH), 6.84 (d, 1H, J = 7.33 Hz, ArH), 6.76 (s, 1H, 
ArH), 5.35 (s, 2H, OCH2), 1.98 (s, 3H, CH3), 1.83  
(s, 6H, 2CH3); 1HRMS (ESI): Calcd for C31H27N6SO5: 
m/z = 595.1758 [M+H]+, found: 595.1726. 
N-(4,6-Dimethylpyrimidin-2-yl)-4-(4-(((4-methyl- 
2-oxo-2H-chromen-7-yl)oxy)methyl)-1H-1,2,3-
triazol-1-yl)benzenesulfonamide 8c: Dark brown 
solid, yield: 72%. m.p.289-290°C; IR (KBr) νmax: 
3511, 3151, 2923, 1718, 1611, 1601, 1425, 1388, 
1367, 1280, 1265, 1204, 1162, 1136, 1072, 1044, 991, 
844, 786, 746, 627, 609, 577, 562, 453 cm-1; 1H NMR 
(400 MHz, DMSO-d6): δ 9.02 (s, 1H, triazole H), 8.04 
(brs, 2H, ArH), 7.90 (brs, 2H, ArH), 7.71 (d, 1H, J = 
7.79 Hz, ArH), 7.61 (s, 1H, ArH), 7.18 (s, 1H, ArH), 
7.08 (brs, 1H, ArH), 6.23 (s, 1H, CH), 5.36 (s, 2H, 
OCH2), 2.40 (s, 3H, CH3), 2.14 (s, 6H, 2CH3); HRMS 
(ESI): Calcd for C25H23N6SO5: m/z = 519.1445 




Dark brown solid. Yield 74%. m.p.232-234°C; IR 




(KBr) νmax: 3448, 2923, 2852, 1734, 1602, 1383, 
1275, 1142, 1082, 1044, 839, 612, 578 cm-1; 1H NMR 
(400 MHz, DMSO-d6): δ 9.07 (s, 1H, triazole H), 8.11 
(brs, 2H, ArH), 8.04 (brs, 2H, ArH), 7.85 (s, 1H, 
ArH), 7.51 (s, 1H, ArH), 6.58 (s, 1H, ArH), 6.30 (s, 
1H, CH), 5.46 (s, 2H, OCH2), 2.40 (s, 6H, 2CH3), 
2.21 (s, 3H, CH3) ppm; 13C NMR (100 MHz, DMSO-
d6): δ 160.38, 159.75, 158.12, 157.70, 156.69, 155.72, 
152.79, 150.45, 150.14, 149.17, 139.06, 129.67, 
126.05, 123.58, 113.98, 112.34, 102.22, 82.97, 64.69, 
18.16; HRMS (ESI): Calcd for C25H22N6SO5Cl: m/z = 
553.1055 [M+H]+, found: 553.1075. 
7-((1-(4-(Piperidin-1-ylsulfonyl)phenyl)-1H-1,2, 
3-triazol-4-yl)methoxy)-2H-chromen-2-one 9a: Off 
white solid. Yield 85%. m.p.221-223°C; IR (KBr) 
νmax: 3084, 3057, 2937, 2852, 2374, 1727, 1615, 
1596, 1505, 1469, 1439, 1400, 1340, 1316, 1281, 
1235, 1204, 1160, 1128, 1096, 1042, 1026, 991, 929, 
891, 851, 837, 802, 782, 758, 723, 710, 603, 583, 457 
cm-1; 1H NMR (400 MHz, DMSO-d6): δ 9.15 (s, 1H, 
triazole H), 8.20 (d, 2H, J = 8.39 Hz, ArH), 8.01 (s, 
1H, J = 8.39 Hz, ArH), 7.95 (d, 2H, J = 8.39 Hz, 
ArH), 7.66 (d, 1H, J = 8.39 Hz, CH),7.20 (d, 1H, J = 
2.29 Hz, ArH), 7.06 (dd, 1H, 1J = 8.39 Hz, 2J = 2.29 
Hz, ArH), 6.31 (d, 1H, J = 8.39 Hz, CH), 5.39 (s, 2H, 
OCH2), 2.94 (t, 4H, J = 5.34 Hz, piperidine H), 1.55 
(q, 4H, J = 5.34 Hz, piperidine H), 1.39-1.35 (m, 2H, 
piperidine H) ppm; HRMS (ESI): Calcd for 




chromen-2-one 9b: Crimson solid. Yield 80%. 
m.p.215-217°C; IR (KBr) νmax: 2927, 2853, 2371, 
1718, 1609, 1507, 1438, 1365, 1342, 1278, 1239, 
1173, 1150, 1125, 1094, 1045, 1029, 1015, 934, 824, 
759, 720, 703, 604, 583cm-1; 1H NMR (400 MHz, 
DMSO-d6): δ 9.14 (s, 1H, triazole H), 8.20 (d, 2H, J = 
8.39 Hz, ArH), 7.94 (d, 2H, J = 8.39 Hz, ArH), 7.57 
(d, 2H, J = 6.87 Hz, ArH), 7.53 (d, 1H, J = 6.87 Hz, 
ArH), 7.32 (d, 2H, J = 6.87 Hz, ArH), 7.26 (d, 1H, J = 
2.29 Hz, ArH), 6.96 (dd, 1H, 1J = 8.39 Hz, 2J = 2.29 
Hz, ArH), 6.85 (d, 1H, J = 8.39 Hz, ArH), 5.38 (s, 2H, 
OCH2), 2.93 (t, 4H, J = 5.34 Hz, piperidine H), 1.83 
(s, 3H, CH3), 1.54 (q, 4H, J = 5.34 Hz, piperidine H), 
1.39-1.34 (m, 2H, piperidine H); 13C NMR (100MHz, 
DMSO-d6): δ 160.96, 160.20, 155.29, 155.16, 147.01, 
144.27, 143.61, 140.51, 139.36, 135.43, 129.57, 
129.37, 123.45, 120.64, 118.51, 112.93, 112.81, 
112.74, 101.65, 61.50, 46.55, 24.65, 22.76, 14.37; 
HRMS (ESI): Calcd for C30H29N4SO5: m/z = 
557.1853 [M+H]+, found: 557.1852. 
4-Methyl-7-((1-(4-(piperidin-1-ylsulfonyl)phenyl)- 
1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one 
9c: White solid. Yield 88%. m.p.235-237°C; IR (KBr) 
νmax: 2929, 1712, 1604, 1502, 1436, 1363, 1340, 
1236, 1168, 1120, 1091, 1014, 935, 827, 756, 702, 
599 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 9.14 (s, 
1H, triazole H), 8.20 (d, 2H, J = 8.24 Hz, ArH), 7.95 
(d, 2H, J = 8.24 Hz, ArH), 7.72 (d, 1H, J = 7.79 Hz, 
ArH), 7.18 (brs, 1H, ArH), 7.08 (d, 1H, J = 7.79 Hz, 
ArH), 6.23 (s, 1H, CH), 5.40 (s, 2H, OCH2), 2.94 (brs, 
4H, piperidine H), 2.40 (s, 3H, CH3), 1.54 (brs, 4H, 
piperidine H), 1.36 (brs, 2H, piperidine H); HRMS 
(ESI): Calcd for C24H25N4SO5: m/z = 481.1546 
[M+H]+, found: 481.1541. 
6-Chloro-4-methyl-7-((1-(4-(piperidin-1-ylsulfonyl) 
phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-
chromen-2-one 9d: Off white solid. Yield 83%. 
m.p.226-228°C; IR (KBr) νmax: 2939, 2852, 1718, 
1608, 1556, 1498, 1446, 1408, 1382, 1340, 1273, 
1207,1157, 1089, 1047, 1018, 983, 933, 898, 840, 
761, 738, 594 cm-1; 1H NMR (400 MHz, DMSO-d6): 
δ 9.15 (s, 1H, triazole H), 8.20 (d, 2H, J = 8.70 Hz, 
ArH), 7.94 (d, 2H, J = 8.70 Hz, ArH), 7.84 (s, 1H, 
ArH), 7.50 (s, 1H, ArH), 6.30 (s, 1H, CH), 5.49 (s, 
2H, OCH2), 2.94-2.91 (m, 4H, piperidine H), 2.39 (s, 
3H, CH3), 1.57-1.51 (m, 4H, piperidine H), 1.37 (brs, 
2H, piperidine H); 13C NMR (100 MHz, DMSO-d6): δ 
159.80, 155.72, 153.19, 152.86, 143.16, 139.37, 
135.48, 129.41, 126.11, 123.76, 120.79, 117.84, 
114.04, 112.38, 102.28, 62.46, 46.61, 24.70, 22.83, 
18.19; HRMS (ESI): Calcd for C24H24N4SO5Cl: m/z = 
515.1156 [M+H]+, found: 515.1128. 
7-((1-(4-(Morpholinosulfonyl)phenyl)-1H-1,2,3-
triazol-4-yl)methoxy)-2H-chromen-2-one 10a: White 
solid. Yield 88%. m.p.228-232°C; IR (KBr) νmax: 
3084, 2921, 2856, 2371, 1726, 1617, 1400, 1349, 
1316, 1282, 1261, 1235, 1203, 1176, 1160, 1127, 
1112, 1071, 1042, 991, 944, 851, 838, 827, 761, 617, 
599, 543, 457 cm-1; 1H NMR (400 MHz, DMSO-d6): 
δ 9.15 (s, 1H, triazole H), 8.23 (d, 2H, J = 8.24 Hz, 
ArH), 8.00 (d, 1H, J = 8.70 Hz, CH), 7.96 (d, 2H, J = 
8.24 Hz, ArH), 7.66 (d, 1H, J = 8.70 Hz, CH), 7.20 (d, 
1H, J = 2.29 Hz, ArH), 7.06 (dd, 1H, 1J = 8.24 Hz, 2J 
= 2.29 Hz, ArH), 6.31 (d, 1H, J = 8.24 Hz, ArH), 5.39 
(s, 2H, OCH2), 3.64 (t, 4H, J = 4.58 Hz, morpholine 
H), 2.93 (t, 4H, J = 4.58 Hz, morpholine H); 13C 
NMR (100 MHz, DMSO-d6): δ 161.01, 160.28, 
155.34, 144.34, 143.71, 139.68, 134.34, 129.68, 




129.63, 123.51, 120.80, 112.99, 122.85, 112.75, 
101.68, 65.30, 61.53, 45.86; HRMS (ESI): Calcd for 




chromen-2-one 10b: White solid. Yield 80%. 
m.p.221-223°C; IR (KBr) νmax: 3120, 2925, 2345, 
1708, 1610, 1355, 1299, 1263, 1166, 1146, 1106, 
1044, 946, 841, 758, 599, 542 cm-1; 1H NMR (400 
MHz, DMSO-d6): δ 9.16 (s, 1H, triazole H), 8.23 (d, 
2H, J = 7.79 Hz, ArH), 7.96 (d, 2H, J = 7.79 Hz, 
ArH), 7.57 (d, 2H, J = 7.79 Hz, ArH), 7.53 (d, 1H, J = 
6.41 Hz, ArH), 7.32 (d, 2H, J = 7.79 Hz, ArH), 7.26 
(s, 1H, ArH), 6.96 (dd, 1H, 1J = 8.70 Hz, 2J = 2.29 
Hz, ArH), 6.85 (d, 1H, J = 8.70 Hz, ArH), 5.38 (s, 2H, 
OCH2), 3.64 (t, 4H, J = 4.58 Hz, morpholine H), 2.93 
(t, 4H, J = 4.58 Hz, morpholine H), 1.83 (s, 3H, CH3); 
13C NMR (100 MHz, DMSO-d6): δ 161.49, 159.95, 
153.40, 150.12, 143.68, 139.64, 138.64, 137.62, 
134.61, 134.27, 130.61, 129.61, 128.87, 128.68, 
128.20, 127.68, 123.42, 120.72, 118.75, 114.00, 
112.73, 101.59, 65.24, 61.46, 45.85, 14.32; HRMS 
(ESI): Calcd for C29H27N4SO6: m/z = 559.1651 
[M+H]+, found: 559.1611. 
4-Methyl-7-((1-(4-(morpholinosulfonyl)phenyl)-
1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one 
10c: Grey solid. Yield 82%. m.p.214-216°C; IR (KBr) 
νmax: 3103, 2923, 2853, 2373, 2345, 1733, 1618, 
1596, 1508, 1443, 1386, 1366, 1353, 1310, 1289, 
1262, 1201, 1166, 1147, 1118, 1098, 1072, 1049, 
1017, 985, 950, 848, 831, 801, 780, 759, 710, 613, 
597, 540, 507, 452cm-1; 1H NMR (400 MHz, DMSO-
d6): δ 9.16 (s, 1H, triazole H), 8.23 (d, 2H, J = 8.39 
Hz, ArH), 7.96 (d, 2H, J = 8.39 Hz, ArH), 7.71 (d, 
1H, J = 9.16 Hz, ArH), 7.18 (d, 1H, J = 2.29 Hz, 
ArH), 7.08 (dd, 1H, 1J = 9.16 Hz, 2J = 2.29 Hz, ArH), 
6.23 (s, 1H, CH), 5.40 (s, 2H, OCH2), 3.64 (t, 4H, J = 
4.58 Hz, morpholine H), 2.93 (t, 4H, J = 4.58 Hz, 
morpholine H), 2.40 (s, 3H, CH3) ppm; 13C NMR 
(100 MHz, DMSO-d6): δ 160.88, 160.12, 154.66, 
153.40, 143.71, 139.67, 134.32, 129.63, 126.58, 
123.48, 120.75, 113.54, 112.63, 111.40, 101.70, 
65.28, 61.51, 45.87, 18.14; HRMS (ESI): Calcd for 




chromen-2-one 10d: Light grey solid. Yield 85%. 
m.p.234-236°C; IR (KBr) νmax: 2974, 1720, 1610, 
1556, 1498, 1448, 1408, 1382, 1348, 1303, 1271, 
1207, 1161, 1107, 1047, 1018, 985, 943, 898, 842, 
765, 740, 715, 596, 543, 501 cm-1; 1H NMR (400 
MHz, DMSO-d6): δ 9.17 (s, 1H, triazole H), 8.24 (d, 
2H, J = 8.70 Hz, ArH), 7.96 (d, 2H, J = 8.70 Hz, 
ArH), 7.85 (s, 1H, ArH), 7.51 (s, 1H, ArH), 6.30 (s, 
1H, CH), 5.49 (s, 2H, OCH2), 3.64 (t, 4H, J = 4.58 
Hz, morpholine H), 2.92 (t, 4H, J = 4.58 Hz, 
morpholine H), 2.40 (s, 3H, CH3) ppm; 13C NMR 
(100 MHz, DMSO-d6): δ 159.83, 155.73, 153.19, 
152.87, 143.23, 134.39, 129.71, 126.12, 123.83, 
120.87, 117.86, 114.06, 112.41, 102.32, 65.35,  
62.44, 45.93, 18.17; HRMS (ESI): Calcd for 




chromen-2-one 11a: Light grey solid. Yield 78%. 
m.p.248-250°C; IR (KBr) νmax: 1720, 1481, 1436, 
1388, 1346, 1271, 1128, 993, 950, 839, 761, 615, 572 
cm-1; 1H NMR (400 MHz, DMSO-d6): δ 9.14 (s, 1H, 
triazole H), 8.21 (brs, 2H, ArH), 8.06 (brs, 1H, 
pyridyl H), 7.98 (brs, 3H, ArH), 7.65 (brs, 1H, ArH), 
7.50 (brs, 1H, ArH), 7.19 (brs, 1H, pyridyl H), 7.06 
(brs, 1H, pyridyl H), 6.80 (brs, 1H, pyridyl H), 6.63 
(brs, 1H, CH), 6.31 (brs, 1H, CH), 5.37 (s, 2H, 
OCH2), 3.60(brs, 4H, piperazine H), 3.03 (brs, 4H, 
piperazine H); HRMS (ESI): Calcd for C27H25N6SO5: 
m/z = 545.1607 [M+H]+, found: 545.1614. 
4-Methyl-7-((1-(4-((4-(pyridin-2-yl)piperazin-1-
yl)sulfonyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
2H-chromen-2-one 11b: Grey solid. Yield 79%. 
m.p.267-269°C; IR (KBr) νmax: 3022, 2360, 1726, 
1481, 1436, 1271, 1199, 1130, 950, 839, 761, 613, 
572 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 9.14 (s, 
1H, triazole H), 8.21 (d, 2H, J = 8.70 Hz, ArH), 8.06 
(d, 1H, J = 5.04 Hz, pyridyl H), 7.98 (d, 2H, J = 8.70 
Hz, ArH), 7.71 (d, 1H, J = 8.24 Hz, ArH), 7.50 (brs, 
1H, ArH), 7.18 (d, 1H, J = 2.29 Hz, ArH), 7.07 (d, 
1H, J = 7.79, pyridyl H), 6.80 (d, 1H, J = 7.79 Hz, 
pyridyl H), 6.64 (d, 1H, J = 5.04 Hz, pyridyl H), 6.23 
(s, 1H, CH), 5.38 (s, 2H, OCH2), 3.61 (brs, 4H, 
piperazine H), 3.04 (brs, 4H, piperazine H), 2.40 (s, 
3H, CH3); HRMS (ESI): Calcd for C28H27N6SO5: m/z 
= 559.1764 [M+H]+, found: 559.1765. 
6-Chloro-4-methyl-7-((1-(4-((4-(pyridin-2-yl) 
piperazin-1-yl)sulfonyl)phenyl)-1H-1,2,3-triazol-4-
yl)methoxy)-2H-chromen-2-one 11c: White solid. 
Yield 75%. m.p.278-280°C; IR (KBr) νmax: 2841, 
1728, 1597, 1498, 1483, 1438, 1409, 1384, 1348, 




1313, 1274, 1242, 1209, 1159, 1118, 1089, 1060, 
1043, 1020, 985, 948, 887, 837, 765, 738, 597, 567 
cm-1; 1H NMR (400 MHz, DMSO-d6): δ 9.16 (s, 1H, 
triazole H), 8.22 (d, 2H, J = 9.16 Hz, ArH), 8.06 (d, 
1H, J = 5.50 Hz, pyridyl H), 7.98 (d, 2H, J = 9.16 Hz, 
ArH), 7.84 (s, 1H, ArH), 7.50 (s, 1H, ArH), 6.80 (d, 
1H, J = 8.70 Hz, pyridyl H), 6.61-6.64 (m, 2H, 
pyridyl H), 6.29 (s, 1H, CH), 5.47 (s, 2H, OCH2), 3.59 
(t, 4H, J = 4.58 Hz, piperazine H), 3.03 (t, 4H, J = 
4.58 Hz, piperazine H), 2.39 (s, 3H, CH3); HRMS 
(ESI): Calcd for C28H26N6SO5Cl: m/z = 593.1374 




In vitro cultivation of asexual stages of P. falciparum 3D7 
Cryopreserved 3D7 strain of P. falciparum was 
revived according to standard protocols and 
introduced into the culture. Asexual erythrocytic 
stages were cultivated using the procedures of Trager 
and Jensen with minor modifications28. The parasites 
were cultivated in RPMI-1640 media containing 2 g/L 
sodium bicarbonate and 40 μg/mL gentamicin 
sulphate, supplemented with 0.5% AlbuMAX-II. 
Human erythrocytes at 10% hematocrit were used to 
culture the parasites, and the cultures were maintained 
at 37ºC in the presence of a mixture of gasses, 5% 
CO2, 5% O2 and 90% N2. The level of parasitemia 
was determined through microscopic examination of 
Giemsa stained thin blood smears. 
 
Antimalarial activity evaluation 
For evaluation of antimalarial activity, [3H]-
hypoxanthine incorporation inhibition assay was 
performed as described elsewhere9. The test 
compounds and chloroquine (positive control) were 
dissolved in DMSO and double-distilled water, 
respectively. The working solutions were prepared in 
RPMI-1640 media and two-fold dilutions were plated 
in 96-well plates in triplicates (final solvent 
concentration <0.5%). Separate wells were prepared 
without the test compounds or chloroquine to monitor 
uninterrupted growth. Asynchronous P. falciparum 
cultures in 2% parasitemia and 4% final hematocrit 
were added to each well. After 24 hours of incubation, 
20 µL of 0.2 µCi/well [3H] hypoxanthine was added 
to each well and the plates were incubated for an 
additional 18 hours. At the end of incubation period, 
the contents in each well were harvested on a glass-
fiber filter mat (Whatman GF/C) using a 96-well 
semi-automated cell harvester (Skatron). The 
radioactive associated nucleic acids on the filters were 
transferred to 5 mL of toluene-based scintillation 
cocktail and radioactive counts were determined using 
liquid scintillation beta-counter (Perkin Elmer 
TriCarb 2900TR). The 50% inhibitory concentration 
(IC50s) values were determined by plotting the drug 




A new series of sulfonamide-attached coumarin-
[1,2,3]-triazole hybrids was synthesized in good  
to excellent yields via Huisgen 1,3-dipolar 
cycloaddition reaction of sulfonamide-based azides 
with various coumarinoalkynes. After spectroscopic 
characterization, the compounds were evaluated  
for their in vitro antimalarial activity against  
P. falciparum (3D7). Out of the twenty-five synthesized 
sulfonamide-based coumarin-[1,2,3]-triazole hybrids, 
four compounds have shown promising antimalarial 
potency with IC50 values <10 µM with a lead 
molecule 7c demonstrating an IC50 value of 3.64 µM. 
Collectively, our results indicate that these four lead 
compounds should be further investigated for their 
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